Multiple sclerosis (MS) is a central nervous system demyelinating disease of implicated autoimmune aetiology. The effect was evaluated of intravenous gammaglobulin (IVIg), a successful therapy in various autoimmune diseases, in relapsing-remitting MS patients treated for three years. IVIg treatment significantly reduced the number and severity of acute exacerbations and resulted in a lesser neurological disability.
Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action A Achiron, R Gilad, R Margalit, U Gabbay, I Sarova-Pinhas, I R Cohen, E Melamed, O Lider, S Noy, I Ziv Abstract Multiple sclerosis (MS) is a central nervous system demyelinating disease of implicated autoimmune aetiology. The effect was evaluated of intravenous gammaglobulin (IVIg), a successful therapy in various autoimmune diseases, in relapsing-remitting MS patients treated for three years. IVIg treatment significantly reduced the number and severity of acute exacerbations and resulted in a lesser neurological disability. There were no significant short or long-term adverse effects to IVIg treatment. To clarify the putative therapeutic effects of IVIg, this treatment was examined in the animal model of experimental autoimmune encephalomyelitis (EAE) in the rat. IVIg suppressed active EAE in relation to disease severity and duration, despite the presence of T-cell reactivity to specific antigens, while the treatment had no effect on passive EAE induced by adoptive transfer of myelin basic protein specific CD4 + T-cells. It is concluded that IVIg treatment may be a promising treatment in relapsing-remitting MS as it can alter the natural course of the disease.
Multiple sclerosis (MS) is the most common central nervous system disease affecting the white matter. Numerous 4 9), respectively] and annual exacerbation rate in the two years before the study, served as controls.
IVIg treatment IVIg (Gamimune N, Miles Inc, Cutter Biological, Promedico, Israel) in a sterile 4 5-5-5% solution of human protein in 9-11 % maltose, was given intravenously once daily for five consecutive days at a dose of 0 4 g/kg/day at the beginning of the study. Thereafter, patients were further treated with booster doses of IVIg, 0-4 g/kg/day, once every two months, for the next three years.
Clinical evaluation Patients were examined before starting the study, and once every month thereafter. Routine urinalysis, complete blood count and chemistry, serological survey of HTLV-1, HIV, and Hepatitis B, and immunoelectrophoresis were performed at entry to the study and at each six month visit. Severity of acute exacerbations was also influenced by IVIg treatment (fig 2) . The majority of exacerbations in the IVIg treated patients were mild to moderate, while in untreated control patients most of the acute exacerbations were moderate to severe (Chisquare = 14-06, p = 0-007). fig 4) . Effect of IVIg treatment on passively induced EAE IVIg had no effect in the treatment of passively induced EAE (fig 5) , in relation to onset, duration and severity. In the IVIg treated rats EAE was mild. The mean maximal EAE score was 1-6 compared with 3 0 in untreated animals (p < 0O05). Duration ment, in spite of the small number of patients included. The decrease in exacerbation rate in the untreated group may be related to the natural course of the disease, reduced stress as a result of participation in a study protocol, or corticosteroid therapy during acute moderate and severe exacerbations. After three years the reduced exacerbation rate in IVIg treated MS patients was correlated with lesser neurological disability, while untreated patients had more exacerbations and increased EDSS score. The beneficial effects of IVIg were also evident in the animal model of EAE. IVIg suppressed active induction of EAE, while it had no effect on passively induced disease. Thus it appears that IVIg can alter immune response before T-cell activation. The results of increased proliferative T-cell responses to target antigens along with active EAE suppression suggest that the mechanism by which IVIg alter the natural course of the disease is not through inhibition of T-cell proliferation. This is further supported by the results of secondary EAE induction, where no disease developed, implying that IVIg suppression of primary induction had no effect on the acquisition of resistance.
Evaluation of acute exacerbations
In conclusion, the use of IVIg in relapsingremitting MS has a significant beneficial effect on the natural course of the disease over time. Though the mechanism by which IVIg modulates the immune system is not yet clear, it probably involves T-cell interactions during the active phase of the disease.
